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ABSTRACT 
CONTINUING PROFESSIONAL DEVELOPMENT PROGRAM 
 ON SECOND-GENERATION ANTIPSYCHOTICS FOR 
 PSYCHIATRIC-MENTAL HEALTH STAFF NURSES 
by Brenda Lee Phillips 
December 2012 
The lack of continuous professional development education regarding second-
generation antipsychotics (SGAs) at a regional state acute care psychiatric hospital limits 
the ability of psychiatric-mental health (PMH) staff nurses to provide care for patients 
with or at risk for metabolic syndrome and other medical problems. The goals of the 
evidence-based program were to (1) examine PMH staff nurses’ knowledge of treatment 
guidelines for schizophrenia and SGAs; (2) provide education on schizophrenia, SGAs, 
and metabolic syndrome; and (3) provide continuous professional development training 
modules on schizophrenia and SGAs electronically for PMH staff nurses in an acute care 
mental health hospital. The effectiveness of the evidence-based program was measured 
by pre and posttest to assess acute care PMH staff nurses’ knowledge of the intervention 
and by an evaluation of the presenter and presentation of the educational program. The 
participants (n = 10) for the continuing professional development (CPD) program were 
RNs (n = 5) and LPNs (n = 5). A statistically significant change was noted in the 
knowledge enhancement among the 10 PMH staff nurses after the implementation of the 
evidence-based educational intervention (t (9) = 5.395, p < .001). The project enhanced 
acute care PMH staff nurses’ knowledge to not only provide medication education to 
patients that are taking SGAs but also to monitor and care for patients with or at risk for             
 iii 
metabolic syndrome associated with taking SGA medications. The psychiatric and mental 
health nurse practitioner (PMHNP) and Doctor of Nursing Practice (DNP) student 
assumed the role as leader in this practice change initiative in order to enhance the 
knowledge of staff nurses and improve patient outcomes. The educational module will be 
completed by all nurses online yearly and updated quarterly based on scientific evidence. 
The Capstone Project provided knowledge for closing the gap between PMH staff nurses 
and care of patients with a diagnosis of schizophrenia who are taking SGAs. 
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CHAPTER I 
INTRODUCTION 
Psychiatric-mental health (PMH) staff nurses face challenges when caring for 
patients with a diagnosis of schizophrenia who take second-generation antipsychotics 
(SGAs) to treat the symptoms of schizophrenia. SGAs tend to pose a problem for the 
patient because of the adverse effect of metabolic syndrome. Patients in acute care 
psychiatric hospitals and PMH staff nurses caring for these patients often have limited 
knowledge of SGAs and fail to understand the risk for metabolic syndrome when taking 
SGAs. A secondary concern is metabolic syndrome associated with SGAs contributes to 
medical problems (e.g., diabetes mellitus, atherosclerosis, and stroke) (Reynolds & Kirk, 
2010). As a result, the patient may experience increased morbidity and health care costs. 
Therefore, PMH staff nurses need to be knowledgeable about schizophrenia and current 
schizophrenia treatment guidelines in order to assess their patients’ medical, as well as 
psychiatric, problems. Acute care PMH staff nurses’ awareness of the increased risk for 
adverse reactions with SGAs and, specifically, ongoing education regarding the 
metabolic side effects associated with SGA medications is vital (Edwards, Rasmussen, & 
Munro, 2010). Continuous professional development (CPD) that provides education on 
SGAs to PMH staff nurses can improve the staff nurses’ knowledge and, ultimately, 
promote positive patient health outcomes. 
Background and Significance 
Schizophrenia is a serious mental illness affecting over two million adults in the 
United States. Among U.S. adults, 58.7% have a serious mental illness (SMI), 7.5% are 
hospitalized, and 52.6% have prescriptions for medications (National Institute of Mental 
Health, 2004). Casey (2005) went further to say “individuals with psychiatric disorders 
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tend to have more illnesses and a shorter lifespan than the general population” (p. 155). 
Patients with schizophrenia have over 300% risk of death secondary to medical reasons 
(Casey, 2005). 
 Schizophrenia affects both genders and is usually diagnosed between late 
adolescence and early adulthood. The age of onset for men is typically between 18 and 25 
years of age, whereas women are usually diagnosed between 25 and the mid-30s. 
Schizophrenia has subtypes such as Paranoid, Disorganized, Catatonic, Undifferentiated, 
and Residual (American Psychiatric Association [APA], 2000). Symptoms associated 
with schizophrenia include delusions (false beliefs), hallucinations (hearing or seeing 
things that are not real), disorganized speech, grossly disorganized or catatonic behavior, 
and other negative symptoms. Antipsychotic medications treat either the positive 
symptoms or positive and negative symptoms of schizophrenia. Typical or first 
generation antipsychotics treat positive symptoms, and atypical or SGAs treat positive 
and negative symptoms. Positive symptoms are due to an excess in the neurotransmitter, 
dopamine, and symptoms exhibited by the patient include hallucinations, delusions, 
thought disturbances, and thought disorganization with bizarre behaviors. Negative 
symptoms are a result of a decrease in dopamine, and patients’ symptoms may include a 
flat or blunted affect, anhedonia (inability to experience pleasure), apathy, ambivalence, 
alogia (paucity of thought), and avolition (inability to focus).   
Patients with schizophrenia who take SGAs are more likely to die from 
cardiovascular illness and are at greater risk for other medical comorbidities including 
obesity, diabetes type 2 (elevated blood glucose), hypertension (elevated blood pressure), 
and dyslipidemias (low HDL and elevated triglycerides) (Lean & Pajonk, 2003). 
Cardiovascular risk factors increased in schizophrenia patients include smoking and high 
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fat diet (Lean & Pajonk, 2003). Many of the SGAs induce weight gain, which increases 
the risk for cardiovascular disease and metabolic syndrome (Gautam & Meena, 2011; 
Keltner, 2006). Metabolic syndrome is a medical term used to describe a multisystem 
disorder. Risk factors associated with metabolic syndrome, such as obesity, hypertension, 
dyslipidemia, and insulin resistance or diabetes mellitus, together increase the risk of 
cardiovascular disease and death (Casey, 2005). Cardiovascular disease risk is two to four 
times higher in schizophrenia patients than those adults without diabetes mellitus (Center 
for Disease Control and Prevention [CDC], 2011). 
Lack of CPD education regarding SGAs at a regional state acute care psychiatric 
hospital limits the PMH staff nurses’ ability to provide care for patients with or at risk for 
metabolic syndrome and other medical problems. Many patients served at this project’s 
acute care psychiatric hospital have developed metabolic syndrome and medical 
problems such as diabetes mellitus because of taking SGAs. In conducting a needs 
assessment at the hospital regarding the nurses’ knowledge of SGAs and monitoring for 
metabolic syndrome, barriers have been identified related to implementing the current 
SGA protocol. The hospital’s current SGA protocol outlines procedures to be completed 
by the PMH staff nurse when monitoring patients for metabolic syndrome: (1) weekly 
weights, (2) fasting plasma glucose, lipid profile, and serum amylase baseline and every 
three months, and (3) obtaining and documenting family history of diabetes mellitus 
when the patient is admitted to the hospital.  The health care provider (HCP) orders 
laboratory tests (i.e., fasting plasma glucose, lipid profile, and serum amylase) every 
three months for patients taking SGAs. PMH staff nurses are responsible for monitoring 
lab results and notifying the patient’s HCP of any abnormal results. Monitoring for 
metabolic syndrome, understanding the need to measure the patient’s abdominal girth and 
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blood pressure, and teaching the patient lifestyle changes were also inconsistently 
addressed by the nurses. The nurses sometimes failed to monitor or report abnormal 
laboratory results to the HCP, warranting education regarding the importance of 
reviewing laboratory results and reporting abnormal results to the patient’s HCP.  
  Staff nurses are not being educated on evidence-based practices to provide care 
and teaching to patients with schizophrenia. Moreover, the PMH staff nurses at the 
hospital tend to be less aware of metabolic syndrome and the medical problems 
associated with SGAs. The PMH staff nurses at the acute care hospital expressed interest 
in additional education and training on how to educate patients at the acute care hospital 
diagnosed with schizophrenia and taking SGAs. After meeting with the chief nurse at the 
hospital, additional knowledge deficits were identified to address with the acute care 
PMH staff nurses. Education on the schizophrenia disease process, SGAs prescribed for 
schizophrenia, and metabolic syndrome associated with SGAs was recommended. 
Professional development provided for the PMH staff nurses annually by the hospital’s 
nurse educator includes a limited overview of SGAs, metabolic syndrome, and 
medication education for patients taking SGAs. PMH staff nurses at the hospital are 
scheduled to provide a medication and health group once a week; however, groups are 
not being done weekly as per protocol. In addition, groups for patients are limited due to 
a lack of education and training provided for the nurses. Development of a CPD will 
increase the PMH staff nurses knowledge on schizophrenia and SGAs in order to provide 
weekly medication education groups as recommended per protocol.  
By educating and training PMH staff nurses, the expected outcome is that 
patients’ awareness of medications prescribed and their potential adverse effects will in 
turn increase. When discharged from the acute care psychiatric hospital, hopefully, 
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patient compliance with continuous treatment from outpatient mental health centers will 
improve. In addition, the patient may ultimately be able to lead productive lives in the 
community. 
PMH staff nurses working in acute care psychiatric hospitals provide care for 
patients with comorbid medical illness in addition to psychiatric diagnoses. Nurses need 
to be educated on SGAs and carefully monitor patients for metabolic syndrome to 
provide cost effective and evidence-based care. More importantly, PMH staff nurses are 
educated in the art and science of nursing in order to help the patient maintain and restore 
health (American Nurses Association [ANA], 2007). Practice focus is on direct patient 
care of patients in clinical settings. When treating patients with schizophrenia, PMH staff 
nurse must implement a treatment plan, develop a therapeutic alliance, promote treatment 
adherence by assessing patient insights about their illnesses, identify cognitive 
impairment barriers and provide education to patient and family (American Psychiatric 
Association [APA], 2004). Specifically, in this facility, direct patient care includes 
providing medication education to patients in group settings. CPD provided to acute care 
PMH staff nurses should include but not be limited to knowledge of schizophrenia, 
SGAs, SGA adverse effects, and interventions to monitor for SGA adverse effect. 
Relevant Literature 
A systematic literature review was conducted to guide the design and 
implementation of an educational program for acute care PMH staff nurses caring for 
patients who are taking SGAs in an acute care psychiatric hospital. The literature search 
was conducted utilizing Cumulative Index of Nursing and Allied Health Literature 
(CINAHL), Academic Search Premier, Google Scholar, Medline, PsychINFO, 
ScienceDirect, and other evidence-based resources. Key terms used in the literature 
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search were acute care mental health hospital, acute care mental health nurses, 
continuous professional development, lifelong learning, metabolic syndrome, obesity, 
schizophrenia, recovery model, and second-generation antipsychotics.  
Schizophrenia and Metabolic Syndrome 
Correll, Fredrickson, Kane, and Manu (2008) examined SGA treatment in 
schizophrenia and mood disorders and effect on dyslipidemia, metabolic syndrome, and 
cardiovascular risk. The study compared 74 patients with bipolar disorder and 111 
patients with schizophrenia receiving SGAs to determine whether metabolic syndrome 
prevalence is influenced by the primary psychiatric diagnosis or concomitant 
mood stabilizers. The study concluded that patients with schizophrenia as well as mood 
disorders treated with SGAs have similar episodes of metabolic syndrome.  
Straker et al. (2005) explored the relationship between SGA and metabolic 
syndrome in 89 acute patients treated with at least one SGA by measuring waist 
circumference, blood pressure, blood glucose and lipids. Using these screenings tools 
makes detection of cardiovascular morbidity in high-risk patients simple and cost 
effective. Furthermore, this project educated nurses on the metabolic adverse effects of 
SGAs. 
Ader et al. (2008) conducted a longitudinal study to examine the effects of 
atypical antipsychotics olanzapine (Zyprexa) and risperidone (Risperdal) on 
glucoregulatory function. A sample of 59 participants from seven U.S. clinical cities 
located in California, Georgia, Texas, and South Carolina were included in a six month 
randomized double blind trial. The sample included individuals between the ages of 18 
and 65 years with a diagnosis of schizophrenia, schizoaffective or schizophreniform 
disorder who were psychiatrically stable and had no hospitalization three months prior to 
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screening. Results of the study were that risperdone and olanzapine increased body 
weight during the entire 24 week treatment period in the groups. The study was the first 
prospective assessment of olanzapine (Zyprexa) and risperidone (Risperdal) effects on 
adiposity and glucoregulatory function in overweight and obese schizophrenia patients 
and showed a drug-induced weight gain among the subjects. Although the results of the 
randomized double blind trial indicated that African Americans and Hispanics have an 
increased risk for diabetes type 2 compared to non-Hispanic Caucasians in the study, pre-
existing risk factors were not examined.  
Components of this educational project addressed schizophrenia, SGAs, adverse 
effects of specific SGAs, and interventions geared to individuals who are at increased risk 
for metabolic syndrome and complications of metabolic syndrome. Patients with 
schizophrenia need an integrated and holistic approach to their care that encompasses 
mental and physical healthcare needs. Promoting healthy lifestyles and monitoring for 
medication side effects, especially if receiving SGAs, are as important as treating the 
positive and negative symptoms of schizophrenia because if untreated the symptoms 
worsen (Llorca, 2008). Therefore, nurses should be aware of the adverse effects of SGAs 
including metabolic syndrome and the physical health problems associated with 
metabolic syndrome to educate and monitor patients.  
Second-Generation Antipsychotic Medications  
In a meta-analysis, Rummel-Kluge et al. (2010) compared metabolic adverse 
effects of seven SGAs (apripirazole [Abilify], amisulpride [Solian], olanzapine 
[Zyprexa], quetiapine [Seroquel], risperidone [Risperdal], sertindole [Serdolect] and 
ziprasidone [Geodon]). The meta-analysis examined weight change as well as blood 
cholesterol and glucose levels. Randomized blinded trials (N = 48) were reviewed to 
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compare metabolic adverse effects of the SGAs including amisulpride (n = 6), 
apriprazole (n = 5), clozapine (n = 11), olanzapine (n = 37), quetiapine (n = 11), 
risperidone (n = 28), sertindole (n = 1) and ziprasidone (n = 6). The study concluded that 
olanzapine showed more weight, cholesterol, and glucose elevation than the other SGAs. 
The study also showed cardiovascular risk factors such as dyslipidemia, smoking, 
obesity, diabetes, and hypertension are more common in patients with schizophrenia.  
Krakowski, Czobor, and Citrome (2009) assessed the association of weight gain 
as well as increased lipids and blood glucose levels with typical antipsychotics and 
atypical antipsychotics in patients diagnosed with schizophrenia, schizoaffective 
disorders, and with a history of physical assault in a state hospital. The randomized 
double blind study showed a significant difference in weight gain, as well as blood 
glucose and lipids increases between clozapine and olanzapine. Patients receiving 
olanzapine gained the most weight; however, patients receiving clozapine had increased 
risk for elevated cholesterol, triglyceride, and glucose. African American patients gained 
more weight taking olanzapine and were more likely to develop metabolic adverse effects 
than Caucasians or Hispanics taking clozapine.  
Edward et al. (2010) summarized research studies to inform novice and 
experienced nurses of knowledge needed to provide care to patients treated with atypical 
antipsychotics medication as well as inform patients of the risk for developing metabolic 
disorders. Assessment, planning, intervention, and evaluation of patients treated with 
antipsychotic medications need to be incorporated in day-to-day nursing care. 
Assessment and interventions include monitoring for metabolic side effects and education 
on the metabolic side effects associated with SGAs.  
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Metabolic Syndrome 
Llorente and Urrutia (2006) explored the complex relationship among psychiatric  
disorders, antipsychotic medications, and risk factors for metabolic syndrome and 
diabetes mellitus. Findings indicated that the prevalence of diabetes mellitus and its risk 
factors are two to four times higher in people with schizophrenia than in the general 
population. An estimate showed that 16% to 25% of people with schizophrenia have 
diabetes mellitus. Additionally, SGAs have contributed to obesity. SGA medication use is 
increasing, and they are associated with an increased risk of weight gain, diabetes, and 
dyslipidemia. Screening for cardiovascular disease and metabolic risk factors is important 
with SGAs. Baseline screening should be completed on all patients and should include 
personal and family history of diabetes mellitus, blood pressure, fasting glucose, and 
serum lipids. Approaches to decrease diabetes mellitus risk include diet and exercise 
counseling and managing blood pressure and cholesterol levels. 
Usher, Foster, and Park (2006) stressed the importance of PMH nurses’ role in 
prevention and ongoing management of patients taking SGAs. They suggested that PMH 
staff nurses must become aware of metabolic syndrome, its association with SGAs, and 
its implications first. With increased metabolic syndrome awareness, PMH staff nurses 
can assist in early symptom detection and have an increased understanding of ongoing 
monitoring and treatment needs. Metabolic syndrome awareness will guide PMH staff 
nurses in educating patients about potential metabolic syndrome associated with SGAs. 
Continuing professional development  
Continuing professional development (CPD) is defined as a process of lifelong 
learning for individuals and teams and, in CPD, the U.S. government focuses on 
outcomes (Hughes, 2005). CPD aims to meet patient needs and promote healthy patient 
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outcomes. CPD education among PMH staff nurses is lacking (Hughes, 2005). CPD for 
PMH staff nurses improves and broadens knowledge and skills required for patient care 
in acute care psychiatric hospitals. CPD is a requirement for acute care PMH staff nurses 
to develop and promote healthy outcomes for patients receiving SGAs. Providing 
education to staff nurses caring for patients with or at risk for metabolic syndrome 
associated with SGAs is important to ensure adherence to evidence-based treatment 
protocols.  
Cleary, Horsfall, O’Hara-Aarons, Jackson, and Hunt (2011) conducted a 
qualitative study to determine clinical PMH nurses’ views and preferences about CPD. In 
this study, nurses (N = 50) from inpatient mental health units were interviewed face-to-
face. An experienced PMH nurse conducted the study over three weeks by rounding on 
the units three to four times a week. Face-to-face interviews (N = 50) with structured 
questions were completed with the nurses in order to gain an understanding of the nurses’ 
perceptions on mental health services and professional development. The majority of the 
participants (n = 47) were registered nurses (RNs), three of which were experienced 
nurses, and, of the 50 participants, four were nurse managers or Clinical Nurse 
Specialists. The results indicated nurses value CPD and sought out more opportunities to 
participate. Nurses expressed desire for CPD and for CPD to be further studied. These 
results are not only timely given the requirements around CPD, but are also important to 
drive improvements in quality CPD in which nurses prioritize, discuss, and agree on 
needs. Study limitations included sampling nurses from one large mental health inpatient 
setting for interviews.  
In conclusion, the review of the literature revealed that patients’ psychiatric as 
well as comorbid medical diagnoses need to be closely monitored while receiving SGAs. 
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PMH staff nurses are obligated to become familiar with assessment and management of 
metabolic syndrome to facilitate improvement in the quality of life for patients with or at 
risk for metabolic syndrome. Failure to recognize metabolic manifestations can increase 
complication risks in the patient. Additionally, the development and implementation of a 
CPD education program designed to make a significant impact on the care quality 
provided to patients with or at risk for metabolic disorders associated with SGAs will be 
beneficial to PMH staff nurses. Finally, PMH staff nurses value this CPD. 
Theoretical Background  
 The recovery model served as the framework that guided this project’s design. In 
this model, nurses are empowered to help patients set goals for their recoveries with 
medication and lifestyles management (Camann, 2010). The recovery model 
acknowledges vulnerabilities associated with mental illness while building strength that 
empowers patients to set goals for recovery. The recovery model focuses on self-
direction, individualized and person-centered care, self-determination and choice, 
motivation, acceptance, and recovery support. The recovery model guided the PMH staff 
nurses in educating the patients on schizophrenia, administering medication, and 
identifying adverse effects of medication. Educating patients on metabolic syndrome 
associated with SGAs will decrease the risk of diabetes mellitus, cardiovascular 
disorders, dyslipidemia, and obesity. Promoting recovery for patients in this project was 
accomplished by increasing PMH staff nurses’ knowledge so that they can provide 
education to patients taking SGAs and setting patient goals for recovery. Furthermore, 
PMH staff nurses supported recovery for the patients by providing education on 
schizophrenia, treatment of schizophrenia with SGAs, metabolic syndrome, and healthy 
lifestyle. 
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Treatment for schizophrenia occurs in three phases: acute, stabilization, and stable 
(APA, 2004). The goal in the acute phase is to reduce agitation and aggression, prevent 
harm during an acute psychotic episode, identify precipitating factors, and return the 
patient to the best functioning level. During the acute phase, the reason for exacerbation 
of symptoms is determined. Laboratory and diagnostic tests such as complete blood 
count, electrolytes, glucose, liver, renal, prolactin, lipid panel, thyroid function test, urine 
toxicology screen, and electrocardiogram are performed. PMH staff nurses need to assess 
baseline signs, symptoms, and laboratory values relevant to monitoring effects of 
antipsychotic medications during the acute phase. Weight, height, body mass index 
(BMI) measurement, diabetes mellitus risk factor screening, and SGAs adverse effects 
monitoring by the PMH staff nurse is critical. 
During the stabilization phase, teaching is implemented to minimize stress on the 
patient and provide support to minimize relapse. The PMH staff nurse assesses for SGAs 
adverse effects and provides patient education regarding schizophrenia and the 
importance of treatment. Finally, the nurse monitors the patient’s weight, blood glucose, 
and other laboratory tests for increased diabetes mellitus and cardiovascular risk during 
the stable phase of schizophrenia.  
Meeting the Doctor in Nursing Practice (DNP) Essentials 
Design and implementation of an evidence-based program is an essential role of 
the Advanced Practice Registered Nurse (APRN) with a Doctor of Nursing Practice 
(DNP) degree (American Association of Colleges of Nursing [AACN], 2006). The DNP 
Essentials of Doctoral Education for Advanced Practice Nursing (AACN, 2006) are met 
through development, implementation, and evaluation of new practice based on evidence-
based knowledge, organizational and systems leadership, clinical scholarship for 
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evidence-based practice, information systems and technology for the improvement and 
transformation of health care,  advocacy in health care, interprofessional collaboration to 
improve patient outcomes, clinical prevention and population health, and advanced 
nursing practice (Appendix A).  
This project offered the opportunity to provide education to acute care PMH staff 
nurses. The information obtained through the evidence-based CPD education program 
enhanced the knowledge of acute care PMH staff nurses providing care for patients 
taking SGAs with or at risk for metabolic syndrome. The design and implementation of a 
CPD education program on SGAs provided for the PMH staff nurses may also lead to 
increased patient knowledge and decreased health care costs at the acute care hospital. 
  Advanced practice nurses apply knowledge, skills, and experience to mental 
health problems in order to promote mental health (ANA, 2007). As nurses’ knowledge is 
enhanced, the expected outcome is that the delivery of care provided to the patients will 
improve. As a psychiatric and mental health nurse practitioner (PMHNP), implementing 
an educational program will improve health outcomes, sustain clinical care, eliminate 
health disparities, and promote patient safety and excellence in care. The PMHNP 
assumed the leadership role to enhance the knowledge of the collaborative team and 
promote positive patient outcomes. Training provided to PMH staff nurses will translate 
to education provided to patients who are taking SGAs.  
The DNP prepared PMH APRN as an effective leader within organizations 
possesses the traits of honesty, integrity, flexibility, and has the ability to lead change 
initiatives and to improve the quality of care provided to patients. Furthermore, positive 
outcomes from the intercollaborative efforts may lead to improvement in the health, well- 
being, and quality of life for patients receiving SGAs in an acute care psychiatric  
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hospital.  
PMH staff nurses face a challenge when caring for patients taking SGAs 
secondary to the metabolic side effects. Many of the patients served at an acute care 
psychiatric hospital have developed metabolic side effects such as diabetes mellitus 
secondary to SGAs. Therefore, PMH staff nurses employed at the acute care hospital 
need to be knowledgeable regarding SGAs and metabolic syndrome as well as the 
concern that SGAs contribute to medical problems. Increasing nurses’ SGA knowledge 
will translate to practice as the nurses provide education to patients.  
Objectives 
 This project’s goal was to design and implement a CPD program on SGAs for a 
cohort of acute care PMH staff nurses using information and communication 
technologies. Specific objectives of the evidence-based program included (1) examine 
PMH staff nurses’ knowledge of treatment guidelines for schizophrenia and SGAs; (2) 
provide education on schizophrenia, SGAs, and metabolic syndrome; and (3) provide 
CPD training modules on schizophrenia and SGAs electronically for PMH staff nurses in 
an acute care mental health hospital. 
This project’s potential implication are that acute care PMH staff nurses will have 
the knowledge not only to provide medication education to patients who are taking SGAs 
in acute care psychiatric hospitals, but also to monitor and care for patients with or at risk 
for metabolic syndrome associated with taking SGA medications. Additionally, the 
program will be incorporated electronically into new nurse orientation, and competency 
will be determined by completion of the program by all nurses yearly. The CPD 
educational program will be updated quarterly by the DNP graduate based on scientific 
evidence. Professional development will be continuous to maintain the knowledge of 
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nurses and members of other professional disciplines caring for patients hospitalized in 
an acute care psychiatric hospital. This education can be provided on other health 
problems that are specific to patients diagnosed with psychiatric disorders. 
The PMHNP DNP student assumed the role as leader in this practice change 
initiative in order to enhance the knowledge of staff nurses and improve patient 
outcomes. The DNP prepared PMH advanced practice nurse’s role is an advocate and 
consultant for other PMH nurses including support for lifelong learning that incorporates 
accountability for practice. The hospital director and chief nurse were notified of the 
project and the project leader was given approval to design and implement a one day 
evidence-based training module for acute care PMH staff nurses.   
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CHAPTER II 
METHODS 
The purpose of this project was to provide a CPD program for PMH staff nurses 
targeting schizophrenia and SGAs. An integrated and holistic approach that encompasses 
mental and physical health care needs of patients hospitalized in an acute care psychiatric 
hospital was implemented. The educational intervention was designed and implemented 
by the project leader for the PMH acute care staff nurses. The intervention was delivered 
at an acute care state psychiatric hospital. A letter requesting permission to implement an 
educational project for PMH staff nurses was provided to the hospital director for 
approval (Appendix B), and approval was received from the hospital director to conduct 
the project (Appendix C). After obtaining approval from the Institutional Review Board 
(IRB) at The University of Southern Mississippi (Appendix D) the educational 
intervention for PMH staff nurses was presented in July 2012 at an acute care mental 
health hospital.  
Setting 
The 180 bed acute care psychiatric hospital in East Central Mississippi provides 
care to more than 500 patients each year and includes nine units: (a) one stabilization 
male unit, (b) one observation male unit, (c) two specialty male units, (d) one vulnerable 
male unit, (e) one transition male unit, (f) one observation/stabilization female unit, (g) 
one vulnerable female unit, and (h) one transition female unit.  
Population  
Participants were staff nurses (N = 10) from the various units. Eligibility criteria 
included full time employment as a RN or Licensed Practical Nurse (LPN) providing care 
for patients on one of the nine units and who worked the 7:00 a.m. to 7:00 p.m. shift. The 
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project excluded PMH staff nurses who worked on the chemical dependency unit or who 
worked the 7:00 p.m. to 7:00 a.m. shift because medication groups we conducted during 
(7:00 a.m. – 7:00 p.m. week days). 
Data Collection and Procedures 
An evidence-based CPD educational program on SGAs was developed and 
provided to a group of PMH staff nurses who worked in an acute care psychiatric facility. 
PMH staff nurses were recruited by placing a flyer (Appendix E) on each unit four weeks 
before delivery of the educational intervention. Prior to the scheduled date for the training 
module RNs and LPNs were notified by the chief nurse. Two weeks prior to 
implementation of the intervention the chief nurse notified the professional development 
director with the number of participants for the educational program. The professional 
development director scheduled the PMH staff nurses to attend the educational program. 
After obtaining the number of potential participants, the project leader notified the chief 
nurse and professional development director of the scheduled day for the evidence-based 
program. The chief nurse notified potential participants from various units regarding the 
scheduled date for the one day program. 
 On the day of the program delivery, a convenience sample of PMH staff nurses 
(N = 10) attended the CPD program in the professional development room of the 
hospital. Participants were provided snacks prior to implementation of the CPD program. 
Prior to the educational intervention, the project leader read an oral presentation to the 
potential participants that described the purpose of the one day evidence-based program 
(Appendix F) and provided a copy of the oral presentation to participants. Participants 
were given the opportunity to ask questions prior to providing informed written consent 
to participate in the program. Participants were then given a consent form (Appendix G). 
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The participants returned the signed consent forms, and the project leader placed the 
signed forms in a locked box. Five RNs and five LPNs were provided the evidence-based 
intervention after obtaining informed consent. The participants were then given a sealed 
packet containing a pretest, posttest, demographic survey, and evaluation form with a two 
digit code provided by the project leader. The code was the identifier for each PMH staff 
nurse participating in the educational program and allowed for tracking of data across 
participants.  
 Prior to implementation of the evidence-based intervention the participants were 
asked to complete a demographic survey form (Appendix H) and a pretest (Appendix I) 
developed by the project leader. The demographic survey collected information regarding 
age, gender, race, occupation, and years of experience as a PMH staff nurse. The pretest 
assessed knowledge of schizophrenia, SGAs, metabolic syndrome associated with SGAs, 
and SGAs adverse effects. After participants completed the pretest and demographic 
survey participants placed surveys in a sealed envelope and returned the sealed envelope 
to the project leader, who placed it in the locked box.  
The evidence-based training program was implemented for the PMH staff nurses 
following collection of the demographic surveys and pretests. The PMH staff nurses were 
educated on schizophrenia, schizophrenia and SGAs, SGAs adverse effects, metabolic 
syndrome monitoring, and educating patients on schizophrenia, SGAs, and metabolic 
syndrome. The educational program was delivered via PowerPoint presentation. After 
completion of the educational program, the participants completed a posttest (Appendix 
I) and a program evaluation form (Appendix J). The posttest and evaluation forms were 
returned in separate sealed envelopes to the project leader, who placed them in the locked 
box. 
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Design 
 The evaluation of this educational project for PMH staff nurses in an acute care 
hospital was a pre and posttest design. A pre and posttest design was used to evaluate 
knowledge attainment as a result of an evidence-based CPD educational program. 
Formative process measures included a demographic survey and a program evaluation 
form to inform future program implementation. 
Demographic Data  
The demographic survey asked participants to choose from categories that 
described their age, gender, race, occupation, and years of experience as a PMH staff 
nurse. 
Pretest and Posttest  
The one day educational program was evaluated by assessing acute care PMH 
staff nurses’ knowledge of the intervention through a pre and posttest (Appendix I) 
design that measured knowledge of schizophrenia, SGAs, metabolic syndrome associated 
with SGAs, and SGAs adverse effects. The pre and posttest consisted of 20 multiple 
choice and true/false questions from the evidence-based training program.  
Program Evaluation  
The evaluation of the evidence-based intervention and the presenter was measured 
 on a 5-point Likert scale (Appendix J). The Likert scale ranged from one to five, 
corresponding respectively with strongly agree to strongly disagree. The Likert scale 
rated the participants’ understanding and delivery of the intervention.   
Ethical and Human Subject Issues 
The risk to participants was minimal in this project. The participants were 
volunteers and not penalized for withdrawal of the project. The participants’ 
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confidentiality and anonymity were protected by placing data collection forms in sealed 
envelopes and in a locked box. Access to the collected data was available to the project 
leader only. After the project’s completion, data collection forms were shredded. 
Data Analysis 
The data from this project included demographic data as well as pretests and 
posttests that were analyzed using paired samples statistics and paired samples tests to 
assess the effectiveness of the intervention on PMH staff nurses knowledge. The 
educational program, as well as the presenter, was evaluated by the participants 
completing a 5-point Likert questionaire. Program evaluation on education of the PMH 
staff nurses on symptoms of schizophrenia, identifying SGA medication, adverse effects, 
understanding metabolic syndrome, attending more CPD programs, and presenter 
knowledge about SGAs and metabolic syndrome were analyzed using descriptive 
statistics. 
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CHAPTER III 
RESULTS 
 The goals of the evidence-based program were to (1) examine PMH staff nurses’ 
knowledge of treatment guidelines for schizophrenia and SGAs; (2) provide education on 
schizophrenia, SGAs, and metabolic syndrome; and (3) provide continuous professional 
development training modules on schizophrenia and SGAs electronically for PMH staff 
nurses in an acute care mental health hospital. 
Analysis of Data 
Demographic Survey 
 Twenty potential participants notified the chief nurse of their interest in 
participating in the educational program. Ten PMH staff nurses attended and consented to 
participate in the educational program. Demographic data for gender, age, race/ethnic 
origin, occupation, and years of experience as a PMH staff nurse was analyzed using 
descriptive statistics. Table 1 shows a summary of demographic data. 
Table 1  
Demographic Data Summary 
 
  Variables 
 
 
N/Percentage 
Gender 
     Females 
     Males 
Age 
     21-29 
     30-39 
     40-49 
Race/Ethnic Origin 
     African American    
 
80% (n = 8) 
20% (n = 2) 
 
 
30% (n = 3) 
40% (n = 4) 
30% (n = 3) 
 
 
50% (n = 5) 
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Table 1 (continued). 
 
 Variables  
 
 
N/Percentages 
     Caucasian 
     Asian/Pacific Islander 
Occupation     
     Licensed Practical Nurse 
     Registered Nurse 
Years experienced as PMH staff Nurse 
     Less than one year 
     1-5 years 
     5-10 years 
     10-15 years 
40% (n = 4) 
10% (n = 1) 
 
 
50% (n = 5) 
50% (n = 5) 
 
30% (n = 3) 
40% (n = 4) 
20% (n = 2) 
10% (n = 1) 
 
The majority of the nurses represented were females (n = 8; 80%). The total number of 
participants (n = 10) was comprised of RNs (n = 5) and LPNs (n = 5). Half (n = 5) of the 
participants were African Americans, and the only male represented was an 
Asian/Pacific/Islander. Of the nurses represented 70% (n = 7) had less than five years of 
experience. Participants in the project ranged from 21 years to 49 years of age. 
Pretest/Posttest Evaluation 
 The PMH staff nurses’ knowledge regarding schizophrenia, schizophrenia and 
SGAs, SGAs adverse effects, monitoring for metabolic syndrome, as well as educating 
patients on schizophrenia, SGAs, and metabolic syndrome was measured prior to and 
after implementation of the educational program. The pretest and posttest consisted of 20 
identical multiple choice and true/false questions. Each correct answer on the test was 
worth 5 points for a total of 100 points. The participants’ pretest scores ranged from 40 to 
80 and posttest scores ranged from 65 to 100. Pretest and posttest data was analyzed with 
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each participant’s overall score using paired t-test sample statistics and paired sample 
test. A statistically significant change in the knowledge enhancement among the 10 PMH 
staff nurses after the implementation of the evidence-based educational intervention was 
noted (t (9) = 5.395, p < .001). The posttest scores were significantly higher than the 
 pretest (Tables 2 and 3). 
Table 2   
Pretest, Posttest Paired Sample Statistics  
 
Paired Sample Statistics 
 Mean               N                        SD                                            SEM 
Pretest             63.5 10                     11.32 3.6 
Posttest            89.5  10                      11.17 3.5 
 
Note. SD = standard deviation. SEM = standard error of the mean 
Table 3 
Paired Samples Test 
 
 
 
Mean 
 
SD 
 
SEM 
 
95% Confidence 
Interval of the 
Difference 
Lower        Upper 
  
t 
 
df 
 
Sig. (2-
tailed) 
Pair1 
pre/ 
post 
-26.00000 15.23884 4.81894 -36.90121 -15.09879 -5.395 9 .000 
 
Note. SD = standard deviation. SEM = standard error of the mean. t = t-test statistic. df = Degrees of freedom.  
Evaluation Plan 
Program Evaluation 
 All participants strongly agreed that they could identify schizophrenia symptoms 
and identify SGA medications. Ninety percent (n = 9) of participants stated the 
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educational intervention provided them with knowledge to educate patients with a 
diagnosis of schizophrenia about SGAs. The majority (n = 8, 80%) of participants were 
able to identify, monitor, and educate patients on adverse effects associated with SGAs 
and metabolic syndrome. All of the participants strongly agreed that a CPD program is 
needed to enhance the knowledge of PMH staff nurses caring for patients with 
schizophrenia (Table 4). An evaluation form using a 5-point Likert scale was analyzed 
using descriptive statistic. Table 4 shows data responses from PMH staff nurses on a 5-
point Likert scale. 
Table 4 
5-Point Likert Program Evaluation 
  
Strongly 
Agree  
Percentages 
 
Somewhat  
Agree 
Percentages 
 
Neutral/No 
Opinion 
Percentages 
 
Somewhat 
Disagree 
Percentages 
 
Strongly 
Disagree 
Percentages 
Can identify 
symptoms of 
schizophrenia  
 
Can identify 
second-
generation 
antipsychotics 
(SGAs) 
 
Can identify 
adverse effects 
of SGAs 
 
Understanding 
of metabolic 
syndrome 
 
Attend more 
CPD programs 
and hospital 
intranet to gain 
information on 
SGAs 
 
100% (n = 10) 
 
 
 
80% (n = 8) 
 
 
 
80% (n =8) 
 
 
100% (n = 10) 
  
100% (n = 10)
    
 
 
 
 
 
 
 
20% (n = 2) 
 
 
 
 
20% (n = 2) 
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Table 4 (continued). 
 
Presenter 100% (n = 10) 
knowledgeable 
on SGAs and 
metabolic 
syndrome 
 
 
Written comments on the educational project evaluation form were provided by 
six participants and include (1) “I obtain [sic] a lot of useful information. Thanks,” (2) “I 
learned so much. You did an excellent job,” (3) “Great job I gained much knowledge,” 
(4) “This presentation was very informative. Excellent job,” (5) “I gained a lot of 
information and will apply the knowledge when caring for my patients,” and (6) “I am a 
new nurse in mental health and this information really did increase my knowledge on 
schizophrenia and metabolic syndrome. I was not aware of the many complications with 
SGAs.” 
 After completion of the evidence-based training program and evaluation of the 
program, the modules were incorporated into new nurse orientation and placed on the 
hospital’s intranet to be completed online by all nurses yearly. The modules will be 
updated quarterly by the DNP graduate based on scientific evidence. The program was 
evaluated for effectiveness with the goal of enhancing acute care PMH staff nurses’ 
knowledge of SGAs (Appendix K). 
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CHAPTER IV 
DISCUSSION 
 The project examined PMH staff nurses’ knowledge of schizophrenia and SGAs, 
and provided education on schizophrenia and SGAs. In addition, the CPD program was 
evaluated prior to developing electronic training modules on schizophrenia and SGAs for 
PMH staff nurses in an acute care mental health hospital. The majority of the participants 
scored lower on the pretest than on the posttest, indicating knowledge attainment as a 
result of the education program. Participants’ scores increased 10 to 20 points after 
implementation of the CPD program; therefore, it is noted that the intervention enhanced 
knowledge to not only provide medication education to patients taking SGAs, but also to 
monitor and care for patients with or at risk for metabolic syndrome. Lastly, the practice 
change initiative project provided CPD training modules on schizophrenia and SGAs 
electronically for PMH staff nurses in an acute care mental hospital. 
Patients with a diagnosis of schizophrenia who take SGA medications to treat the 
symptoms of schizophrenia need to be routinely monitored for metabolic syndrome. 
Meyers and Stahl (2009) found that schizophrenia patients have an increased risk for 
cardiovascular disease secondary to lifestyle, disease process, and action of medication 
prescribed. It is vital that mental health providers and PMH acute care staff nurses screen 
patients taking SGAs for metabolic disorder in order to decrease risk for cardiovascular 
disease. More importantly, Straker et al. (2005) found that screening is simple and cost-
effective in detecting for cardiovascular disease in high-risk patients. Although CPD 
education among PMH staff nurses is lacking (Hughes, 2005), PMH staff nurses were 
able to identify schizophrenia manifestations after delivery of the educational program 
for this project. PMH staff nurses were also able to identify SGA medications and their 
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adverse effects. Specifically, the project increased the nurses’ understanding of metabolic 
syndrome associated with SGAs. A statistically significant change in the knowledge 
enhancement among the PMH staff nurses after the implementation of the evidence-
based educational intervention was noted. Cleary et al. (2011) determined that 
professional education has the potential to improve job satisfaction and positively 
influence patient care. Educating PMH staff nurses on schizophrenia, SGAs, metabolic 
syndrome associated with SGAs, and SGAs adverse effects may improve the quality of 
care provided to the patients. The educational program provided a building block for 
educational preparation for PMH staff nurses to educate their patients. PMH staff nurses 
were provided knowledge to guide patients about making healthy lifestyle choices to 
improve quality of life. 
The CPD educational intervention was limited to a six hour program for PMH 
staff nurses at a single mental health hospital in East Central Mississippi. The sample size 
was rather smaller than expected for the program. Participation in the program may have 
been low because the PMH staff nurses who worked 7:00 p.m. to 7:00 a.m. were 
excluded from the program. On the day of the program delivery, attendance was also low 
because PMH staff nurses who had originally expressed interest in attending the program 
had to accompany patients to a cookout provided by the hospital. More efforts should be 
put into recruitment in the future such as spending time with PMH staff nurses on the 
other shift and providing the educational intervention at a time that is convenient for the 
hospital and PMH staff nurses on both shifts. The CPD intervention should be delivered 
to members of other disciplines in the hospital, including social workers, psychology 
workers, recreational workers, and direct care workers. The modules should also be made 
available regionally and state wide for acute care PMH staff nurses at other acute care 
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mental health hospitals. The DNP graduate will continue to be the driving force to 
provide education to PMH staff nurses as well as other interdisciplinary team members to 
help patients understand illness and lifestyles changes. 
When looking at demographic characteristics of the participants, a majority of the 
participants were females and had been employed between one and five years as PMH 
staff nurses. A need to incorporate the CPD program into the new employee orientation 
for nurses who lack experience was identified. The PMH staff nurses receive educational 
training regarding schizophrenia and SGAs once a year; however, training on metabolic 
syndrome is lacking. In evaluating the CPD program, all of the participants strongly 
agreed that CPD programs are needed. Providing CPD training on the hospital’s intranet 
on schizophrenia and metabolic syndrome enhances the PMH staff nurses’ knowledge. 
The CPD education program was designed to make a significant impact on the quality of 
care provided to patients with or at risk for metabolic disorders associated with SGAs.  
The framework used for this project was the recovery model to empower nurses 
to help patients set goals for their recoveries through medication and lifestyle 
management (U.S. Department of Health and Human Services, Substance Abuse and 
Mental Health Services Administration Center for Mental Health Services [SAMHSA], 
2006). The project leader’s mental health knowledge directed the design, implementation, 
and evaluation of the evidenced-based educational intervention for PMH staff nurses. The 
PMHNP DNP student assumed the role as leader in this practice change initiative in order 
to enhance the knowledge of staff nurses and improve patient outcomes. A knowledge 
and practice gap in providing care to the patients with metabolic syndrome associated 
with SGAs exists in the acute care mental health hospital between PMH staff nurses and 
continuing professional development. Therefore, CPD training modules on schizophrenia 
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and SGAs were placed electronically in an acute care mental health hospital for nurses to 
complete online yearly. Future plans include a quarterly update of the hospital’s intranet 
modules based on scientific evidence. The DNP graduate will continue to monitor the 
implementation of the educational program in new nurse orientation for PMH staff nurses 
to see continuous success in gaining knowledge and needed areas of improvement.   
Recommendations for further evaluation are to continue the DNP prepared PMH 
advanced practice nurses’ role as advocate and consultant for other acute care PMH staff 
nurses including support for lifelong learning that incorporates accountability for practice 
in acute care psychiatric hospitals. The DNP graduate will provide CPD programs to 
maintain the knowledge of nurses and other professional disciplines caring for patients 
hospitalized in an acute care psychiatric hospital. Education provided to members of 
other disciplines including social workers, psychology workers, recreational workers, and 
direct care workers will be geared to providing evidence-based information relevant to 
their discipline. The DNP prepared advanced practice nurse will provide acute care PMH 
staff nurses with education on other health problems that are specific to individuals 
diagnosed with psychiatric disorder. In addition to providing ongoing education to acute 
care PMH staff nurses, the CPD programs on schizophrenia, SGAs, SGAs adverse 
effects, and metabolic syndrome will be provided to PMH staff nurses who work in the 
adolescent and nursing home services of the hospital. The DNP PMH advanced practice 
nurse will continue to be the driving force to enhance knowledge of other disciplines in 
helping to improve patient outcomes and decrease health care costs for patients taking 
SGAs with or without risk for metabolic syndrome. Long term goals are to promote a 
safe practice environment and improve health outcomes for patients with or at risk for 
metabolic syndrome. Early identification of SGAs adverse effects may decrease 
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metabolic syndrome, such as diabetes mellitus, obesity, and dyslipidemia, in patients with 
schizophrenia. 
The implementation of the educational intervention enhanced acute care PMH 
staff nurses’ knowledge in not only providing medication education to patients who are 
taking SGAs, but also in monitoring and caring for patients in an acute care psychiatric 
hospital with or at risk for metabolic syndrome associated with SGA medications.  This 
project has provided a foundation for closing the gap between the PMH staff nurses’ 
knowledge and professional development.  
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APPENDIX A 
MEETING THE DOCTOR OF NURSING PRACTICE (DNP) ESSENTIALS 
DNP Essentials DNP Essential Outcome  
Essential I – Scientific 
Underpinnings for practice 
Utilized scientific evidence and the Recovery Model to 
develop, implement and evaluate a new practice 
approach, a continuous professional development 
educational intervention for acute care Psychiatric 
Mental Health staff nurses  
Essential II – Organizational 
and System Leadership for 
Quality Improvement and 
Systems Thinking 
Developed an educational intervention for psychiatric 
mental health staff nurses to increase their knowledge 
about schizophrenia and SGAs in order to ensure 
quality health care, patient safety, and positive 
outcomes for patients in an acute care mental health 
facility 
 
Essential III – Clinical 
Scholarship and Analytical 
Methods for Evidence-Based 
Practice 
Reviewed  scientific literature databases and evidence-
based treatment guidelines to design and implement an 
evidence-based intervention  
Essential IV – Information 
Systems/Technology and 
Patient Care Technology for 
the improvement and 
Transformation Health Care 
Assessed evidence-based information related to 
educating PMH staff nurses about SGAs and metabolic 
syndrome. Provided continuous professional 
development training modules on schizophrenia and 
SGAs electronically for PMH staff nurses in an acute 
care mental health hospital.  
Essential V – Health Care 
Policy for Advocacy in 
Health Care 
Assumed leadership in implementation of institutional 
policy. Assumed role of leader in educating PMH staff 
nurses on Recovery Model for educating patients to 
promote cost effective healthy outcomes. Influenced 
and advocated for safe cost effective care with positive 
outcomes for the adult client with a psychiatric 
diagnosis that is taking SGAs medication. 
Essential VI – 
Interprofessional 
Collaboration for Improving 
Patient and Population Health 
Outcomes 
Employed consultative and leadership skills with 
intraprofessional and interprofessional teams to create 
change in health care. Collaborated with the chief nurse 
and nurse educator to enhance knowledge to acute care 
PMH staff nurses to educate patients on schizophrenia, 
SGAs, metabolic syndrome associated with SGAs, and 
adverse effects of SGAs to generate positive outcomes. 
Essential VII – Clinical 
Prevention and Population 
Health for Improving the 
Nation’s Health 
Analyzed current data to manage risk to schizophrenia 
patients taking SGAs. Interventions designed for acute 
care staff nurses caring for schizophrenic patients will 
enable patients to increase control over their health and 
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address gaps between knowledge and practice related to 
individual care. 
Essential VIII – Advanced 
Nursing Practice 
 
 
Conducted a comprehensive and systematic assessment 
of systems issues to design and implement evidence-
based training modules to enhance PMH staff nurses 
knowledge to not only educates but care for patients in 
an acute care mental health hospital.  
Provided guidance, mentoring, and support to acute 
care PMH staff nurses to achieve excellence in nursing 
practice. The project leader’s role as consultant-liasion 
and expert mental health knowledge directed the 
design, implementation, and evaluation of the 
evidenced-based educational intervention for PMH staff 
nurses 
 
Note. American Association of Colleges of Nursing, 2006    
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APPENDIX B 
REQUEST FOR PERMISSION LETTER 
Brenda Phillips  
1901 34th Avenue  
Meridian, MS 39301  
March 1, 2012  
 
Charles Carlisle  
Director East Mississippi State Hospital  
4555 Highland Park Drive  
Meridian, MS 39307  
 
Dear Mr. Charles Carlisle:  
I am a student at the University of Southern Mississippi, Hattiesburg, MS pursuing a 
degree in the Doctor of Nursing Practice program. For my capstone project I would like 
to design and implement an educational program for the in-patient mental health nurses at 
the facility caring for patients on Second-Generation Atypical anti psychotics (SGA). The 
educational program will include knowledge of SGA anti psychotics, side effects of SGA 
antipsychotics and promote continuous professional development for the in-patient 
mental health nurses.  
 
Verbal permission from you as well as the Chief Nurse has allowed me to do clinical 
hours at the facility. I have received verbal permission from the Chief Nurse to design 
and implement an educational program to the in-patient mental health nurses. Presently I 
am doing clinical hours at the mental health facility and will continue my clinical hours 
through the summer. I would like to implement the educational program in August, 2012.  
 
Mental health nurses working in inpatient psychiatric facilities provide care for patients 
with comorbid medical illness in addition to psychiatric diagnoses. However, nurses' 
caring for mentally ill patients at the hospital lacks knowledge of metabolic disorders 
associated with SGA antipsychotics. The implementation of the educational program will 
enhance the knowledge of the nurses and improve the delivery of care provided to the 
patients.  
 
If you have questions, please contact me by email at Lildoll841@aol.com or phone at 
(601) 513- 5482. 
   
 
Brenda Phillips, PMHNP-BC  
USM Doctor of Nursing Practice Student 
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APPENDIX C 
LETTER OF APPROVAL FROM DIRECTOR EAST MISSISSIPPI STATE 
HOSPITAL 
 
EAST MISSISSIPPI STATE HOSPITAL  
P.O. BOX 4128, WEST STATION, MERIDIAN, MISSISSIPPI 39304-4128 
  
Charles S Carlisle, Director 
 Ph. (601) 581-7600 
 Fax (601) 483-5543  
 
 
April 16, 2012  
Brenda Phillips  
1901 34th Avenue  
Meridian, MS 39301 
  
Dear Ms. Phillips:  
We are pleased to have you in our facility as well as to have your insight shared with our 
psychiatric mental health nurses. The design and implementation of your educational 
program on second-generation antipsychotics associated with metabolic syndrome will 
certainly benefit the nurses and the individuals we serve at our facility. Again, we are 
elated about the knowledge you will provide to us and are pleased to be a part of your 
program.  
If I can provide any further information, please contact my office.  
 
  
Charles Carlisle  
Hospital Director  
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Appendix D 
LETTER OF APPROVAL INSTITUTIONAL REVIEW BOARD 
  
 
INSTITUTIONAL REVIEW BOARD  
 
118 College Drive #5147 | Hattiesburg, MS 39406-0001 Phone: 601.266.6820 | Fax: 601.266.4377 | 
www.usm.edu/irb 
 
NOTICE OF COMMITTEE ACTION 
The project has been reviewed by The University of Southern Mississippi Institutional 
Review Board in accordance with Federal Drug Administration regulations (21 CFR 26, 
111), Department of Health and Human Services (45 CFR Part 46), and university 
guidelines to ensure adherence to the following criteria:  
 
The risks to subjects are minimized. □The risks to subjects are reasonable in relation to 
the anticipated benefits. □The selection of subjects is equitable. □Informed consent is 
adequate and appropriately documented. □Where appropriate, the research plan makes 
adequate provisions for monitoring the data collected to ensure the safety of the 
subjects. □Where appropriate, there are adequate provisions to protect the privacy of 
subjects and to maintain the confidentiality of all data. □Appropriate additional 
safeguards have been included to protect vulnerable subjects. □Any unanticipated, 
serious, or continuing problems encountered regarding risks to subjects must be reported 
immediately, but not later than 10 days following the event. □This should be  reported  to  
the  IRB  Office  via  the  “Adverse Effect  Report  Form”. □If approved, the maximum 
period of approval is limited to twelve months. 
 
Projects that exceed this period must submit an application for renewal or continuation. 
 
PROTOCOL NUMBER: 12052303 □PROJECT TITLE: Continuing Professional 
Development Program on Second Generation Antipsychotics for Acute Care 
Psychiatric-Mental Health Nurses □PROJECT TYPE: New Project 
□RESEARCHER/S: Brenda L. Phillips □COLLEGE/DIVISION: College of 
Health □DEPARTMENT: Nursing □FUNDING AGENCY: N/A □IRB COMMITTEE 
ACTION: Expedited Review Approval □PERIOD OF PROJECT APPROVAL: 
05/29/2012 to 05/28/2013 
Lawrence A. Hosman, Ph.D. Institutional Review Board Chair 
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APPENDIX E 
RECRUITMENT FLYER 
Continuing Professional Development Program on 
Second-Generation Antipsychotics for Acute Care 
Psychiatric-Mental Health Staff Nurses 
 
Psychiatric-Mental Health Staff Nurses 
Needed To 
Participate in an Educational Project 
In Professional Development 
July 2012  
If you are interested in participating, please inform the Chief 
Nurse  @ ext. 17821 or email: dnobles@emsh.ms.gov 
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APPENDIX F 
ORAL PRESENTATION 
 Good afternoon. I am Brenda Phillips, a psychiatric mental health nurse 
practitioner and a Doctor of Nursing Practice student at The University of Southern 
Mississippi. Research has shown that metabolic syndrome is a problem with adult 
patients that take second-generation antipsychotics as pharmacological treatment for 
psychiatric diagnoses. Psychiatric-mental health nurses with limited knowledge of SGAs 
fail to understand the risk for metabolic syndrome with these medications. 
 The goal of this project is to design and implement a continuing education 
program on second-generation antipsychotics for a cohort of acute care psychiatric-
mental health nurses. The evidence-based program will (1) examine PMH staff nurses’ 
knowledge on education and treatment guidelines for schizophrenia and SGAs in an acute 
care mental health hospital, and (2) promote continuous professional development for 
PMH staff nurses in an acute care mental health hospital through providing training 
module on intranet to enhance knowledge for educating their patients. The participation 
in this program will take approximately one day. 
 You will be administered a pretest to assess knowledge of schizophrenia, second-
generation antipsychotics (SGAs), metabolic syndrome associated with SGAs, and 
monitoring for metabolic syndrome and complications of metabolic syndrome. After 
taking the pretest, the pretest will be returned to the presenter and placed in a locked box 
where only the presenter will have access. The educational program will then be 
presented and consists of a PowerPoint presentation designed to enhance the knowledge 
of PMH staff nurse so that they can better educate hospitalized patients with 
schizophrenia on SGAs. At the end of the program, you will be administered a posttest to 
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assess the knowledge gained from the program and allowed to ask questions. You will be 
asked to evaluate the continuing professional development program and presenter. 
 The project will be an ongoing process for PMH staff nurses’ to gain knowledge 
regarding mental illness associated with SGAs for the professional development 
department. The evidence-based program will enhance the knowledge of acute care 
psychiatric-mental health nurses providing medication education to patients taking SGAs. 
The risk to participants will be minimal in this program. You will not be penalized for 
withdrawal from program; however, you will be removed from program if not present for 
the entire day. You will be given an envelope with a code to assure confidentiality and 
anonymity during the program. You place the code on all information provide to you 
during the program. The data will be collected, placed in a locked box and kept with the 
researchers for 6 months and then discarded. 
 This project has been reviewed by the Institutional Review Board, which ensures 
that research projects involving human subjects follow federal regulations. Any questions 
or concerns about rights as a research participant should be directed to the Chair of the 
Institutional Review Board at the University of Southern Mississippi 601-266-6820. 
Participation in this project is completely voluntary, and participants may withdraw from 
this study at any time without penalty, prejudice, or loss of benefits. Any questions about 
the research should be directed to: 
Anita Davis Boykins, DNSc, FNP-BC, PMHNP-BC 
Assistant Professor, School of Nursing 
University of Southern Mississippi 
118 College Drive #5095 
Hattiesburg, MS 39406-0001 
Telephone: 601-266-5468 
Fax: 601-266-6643 
Anita.boykins@usm.edu 
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Brenda Phillips, MSN, RN, PMHNP-BC 
DNP Student 
University of Southern Mississippi 
Brenda.phillips@usm.edu 
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APPENDIX G 
WRITTEN INFORMED CONSENT 
(Sample Consent Short Form — to be used with oral presentation) 
 
THE UNIVERSITY OF SOUTHERN MISSISSIPPI 
 
AUTHORIZATION TO PARTICIPATE IN RESEARCH PROJECT 
 
Participant's Name _____________________________ 
Consent is hereby given to participate in the research project entitled Continuing 
Professional Development Program on Second-Generation Antipsychotics for Acute Care 
Psychiatric-Mental Health Nurses. All procedures and/or investigations to be followed 
and their purpose, including any experimental procedures, were explained by Brenda 
Phillips. Information was given about all benefits, risks, inconveniences, or discomforts 
that might be expected. 
 
The opportunity to ask questions regarding the research and procedures was given. 
Participation in the project is completely voluntary, and participants may withdraw at any 
time without penalty, prejudice, or loss of benefits. All personal information is strictly 
confidential, and no names will be disclosed. Any new information that develops during 
the project will be provided if that information may affect the willingness to continue 
participation in the project. 
 
Questions concerning the research, at any time during or after the project, should be 
directed to Brenda Phillips, 601-513-5482. This project and this consent form have been 
reviewed by the Institutional Review Board, which ensures that research projects 
involving human subjects follow federal regulations. Any questions or concerns about 
rights as a research participant should be directed to the Chair of the Institutional Review 
Board, The University of Southern Mississippi, 118 College Drive #5147, Hattiesburg, 
MS 39406-0001, (601) 266-6820. 
 
________________________________   ______________________ 
Signature of participant     Date 
 
________________________________   ______________________ 
Signature of person explaining the study    Date 
 
 
41 
 
 
APPENDIX H 
DEMOGRAPHIC FORM 
Please circle the appropriate letter.   
1. Age:  
A. 20 – 29 
B. 30 – 39 
C. 40 - 49 
D. 50 – 59 
E. 60 or above  
2. Gender:  
A. Male 
B. Female   
3. Race:  
A. American Indian/Alaskan Native 
B. Asian/Pacific Islander 
C. African American/Non-Hispanic 
D. Caucasian/Non-Hispanic 
E. Hispanic 
F. Other _____________   
4. Occupation: 
A. Licensed Practical Nurse 
B. Registered Nurse  
5. Years of experience as a Psychiatric-Mental Health staff nurse  
A. Less than 1 year 
B. 1 – 5 years 
C. 5 – 10 years 
D. 10- 15 years 
E. 15 years or above  
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APPENDIX I 
Pretest/Posttest 
Continuing Professional Development Program on Second-Generation Antipsychotics for   
Acute Care Psychiatric-Mental Health Staff Nurses 
Place circle the appropriate answer. 
_____1.  Patients with schizophrenia receiving second-generation antipsychotics are 
more likely to die from which of the following: 
a. Hypertension 
b. Dyslipidemias 
c. Cardiovascular Problems 
d. Diabetes Type 2 
_____2.  Of patients who gained weight while receiving an atypical antipsychotic 
agent,  patients with a ____________ gained the most weight. 
  
                             a. Body mass index (BMI 25.0-29.9) 
     b. Body mass index (BMI >30) 
     c. Body mass index (BMI <25) 
     d. Low serum cholesterol level 
 
_____ 3. Which medications treat both positive and negative symptoms of 
schizophrenia? 
a. Typical (first generation antipsychotics) 
b. Haldol 
c. Prolixin 
d. Atypical (second generation antipsychotics) 
 
_____ 4.  The following medications are second-generation antipsychotics except: 
a. Olanzapine (Zyprexa) 
b. Apripiprazole (Abilify) 
c. Loxapine (Loxitane) 
d. Quetiapine (Seroguel) 
 
_____ 5. All SGA medications have anticholinergic side effects.  
True or False 
_____ 6.  All of the following medications have the potential for glucose and lipid            
      abnormalities except: 
a. Risperdone  (Risperdal) and Quetiapine (Seroquel) 
b. Ziprasidone (Geodon) and Olanzapine (Zyprexa)  
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c. Aripiprazole (Abilify) and Ziprasidone  (Geodon) 
d. Clozapine (Clozaril) and Olanzapine (Zyprexa) 
_____ 7.    Metabolic syndrome is a multisystem disorder associated with obesity, 
                 diabetes hypertension and dyslipidemia.   
 
                 True or False 
 
_____ 8.   All of the following factors increase an individual with schizophrenia risk 
        for metabolic syndrome except: 
a. Increasing tendency of less physical activity 
b. High caloric diet resulting in obesity 
c. Small waist circumference 
d. Adverse effects of SGA antipsychotics 
_____ 9.   The SGA which  has the maximum potential to cause increase weight gain  
        is: 
a. Risperidone (Risperdal) 
b. Olanzapine  (Zyprexa) 
c. Aripiprazole (Abilify) 
d. Ziprasidone (Geodon) 
 
_____ 10.  The SGA which has the potential for increase cholesterol is: 
a. Risperidone (Risperdal) 
b. Olanzapine (Zyprexa) 
c. Aripiprazole (Abilify) 
d. Ziprasidone (Geodon) 
_____11.   What is a common adverse effect of second-generation antipsychotics? 
 
    a.   High cholesterol level 
     b.   weight gain  
     c.   altered glucose intolerance and insulin secretion 
     d.   All of the above 
 
_____12.   Continuing professional development is focused on outcomes and is 
                  defined as a process of lifelong learning for all individuals and teams.  
 
True or False 
_____13.   Important topics that the psychiatric-mental health staff nurse should   
       provide education on to patients taking SGAs include: 
a. Healthy diet 
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b. Weight weekly 
c. Moderate exercise 
d. All of the above 
_____14.   Smoking and high fat diet are cardiovascular risk factor in patients with 
                  schizophrenia.  
 
 True or False 
_____15.   What phase of schizophrenia treatment should the nurse begin education 
                   about the course of the illness and importance of treating schizophrenia?  
a. stable 
b. acute 
c. stabilization 
d. transition 
_____16.    Which SGA has contributed to an increase of patients being diagnosed  
        with or being at risk for developing Type 2 diabetes? 
a. Depakote (Dapakene) 
b. Olanzapine (Zyprexa) 
c. Quetiapine (Seroquel) 
d. Chlorpromazine (Thorazine) 
 
_____17.     Patients’ with schizophrenia psychiatric as well as comorbid medical 
          illnesses need to be monitored by PMH staff nurses while receiving SGA.  
 
  True or False 
 
_____ 18.     Dyslipidemia includes: 
a. High triglycerides 
b. Low HDL cholesterol 
c. High blood pressure 
d. a & b 
_____19.     All labs except the following are to be obtain baseline and every three (3)  
         months for patients taking SGAs. 
a. Fasting plasma glucose 
b. Fasting serum lipid 
c. Serum amylase 
d. Prothrombin 
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______20.    The neurotransmitter deregulations theory of the etiology of psychotic   
                     disorders such as schizophrenia support that psychosis is caused, in part, by: 
 
a. An excess of dopamine 
b. A deficiency of dopamine 
c. An imbalance of dopamine and GABA 
d. Poor synaptic uptake of serotonin receptors 
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APPENDIX J 
PROGRAM EVALUATION 
Please evaluate the presentation by providing how well the program objectives were met 
using the following scale:     
 
1-Strongly agree     2-Somewhat agree     3-Neutral/no opinion     4-Somewhat disagree   5-Strongly 
disagree 
1.  I can identify signs/symptoms of schizophrenia.    1      2      3      4      5 
2.  I can identify which medication are second generation antipsychotics.    
       1      2      3      4      5 
3. I can identify adverse effects of second generation antipsychotics.    
       1      2      3      4      5 
4. The program increased my understanding of metabolic syndrome 
1    2      3      4      5 
5. The program provided knowledge that will help me in providing medication education 
    to patients diagnosed with schizophrenia that are taking second generation 
    antipsychotics        1      2      3      4     5  
6. I would like to attend more continuous professional development programs    
       1     2      3      4      5 
7. Was the presenter knowledgeable about second generation antipsychotics and  
 
    metabolic syndrome?        
       1      2      3      4      5 
8. Please share recommendations and suggestions to be made 
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APPENDIX K 
EVALUATION PLAN 
Project Objectives Activities Evaluation Outcomes 
Examine PMH staff nurses’ 
knowledge on treatment 
guidelines for schizophrenia and 
SGAs  
 
Provide education on 
schizophrenia, SGAs, and 
metabolic syndrome Provide 
education on schizophrenia and 
SGAs 
 
 
 
 
 
 
Evaluate the educational 
program 
 
 
 
 
 
 
 
 
Pretest  
 
 
 
 
PowerPoint 
presentation on 
schizophrenia, SGAs, 
and metabolic 
syndrome 
 
Posttest  
 
  
 
 
 
 
 
Pretest results ranged 40 to 
80 with a mean of 63.5 
 
 
 
 
 
 
 
 
 
 
There was a statistically 
significant change in the 
retention of knowledge 
among the 10 PMH staff 
nurses after presentation of 
the educational intervention 
(t (9) = 5.395, p < .001. 
 
-PMH acute care staff  nurses  
were able to identify 
symptoms of schizophrenia 
-All of the PMH staff (n = 
10; 100%) nurses were able 
to identify SGA medication 
for administration of 
schizophrenia. 
-The majority of PMH staff 
nurses (n = 8; 80%) were able 
to identify monitor and 
educate patients on adverse 
effects associated with SGAs. 
-Most of the participants 
were able to identify factors 
associated with metabolic 
syndrome in order to educate 
the patients. 
-The participants strongly 
agreed for the need of 
attending continuous 
professional development 
program. 
-All of the participants stated 
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they will go to hospital 
intranet to obtain updated 
information based on 
scientific evidence. 
Provide continuous professional 
development training modules on 
schizophrenia and SGAs 
electronically for PMH staff nurses 
in an acute care mental health 
hospital 
Modules provided on 
hospital intranet and 
updated quarterly with 
scientific evidence 
The modules were 
incorporated into new nurse 
orientation and placed on the 
hospital’s intranet.                               
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